Milestone Scientific Inc. reported a total revenue of approximately $8.97 million for the fiscal year ending December 31, 2025, marking a 4% increase from the previous year's revenue of $8.63 million. The growth was primarily driven by a rise in international sales, particularly in the dental segment, which accounted for about $8.79 million of total sales, up from $8.53 million in 2024. Medical product sales also saw an increase, reaching $183,250 compared to $104,620 in the prior year. Despite the revenue growth, the company continued to experience significant operating losses, reporting a net loss of $5.72 million, an increase from a loss of $4.71 million in 2024.
The company's financial performance reflects a strategic shift in its operations, with a focus on cost containment and efficiency. Total operating expenses decreased to approximately $12.1 million in 2025 from $13.2 million in 2024, largely due to reductions in selling, general, and administrative expenses, as well as research and development costs. The gross profit margin declined to approximately 71% from 75% in the previous year, attributed to changes in product mix and cost structure. The company has also reduced its workforce, leading to a decrease in salary expenses by 17%.
Milestone Scientific has made significant strides in its product offerings, particularly with its CompuFlo Epidural Computer Controlled Anesthesia System, which received expanded FDA clearance in 2023 for use in the thoracic region. The company is actively pursuing additional regulatory clearances and commercial opportunities, including exploring potential applications for its Dynamic Pressure Sensing technology in various medical settings. The STA Single Tooth Anesthesia System has been used for over 95 million injections globally, indicating strong market adoption.
Operationally, Milestone Scientific has faced challenges, including reliance on third-party manufacturers for its products, which exposes the company to risks related to supply chain disruptions and quality control. The company employed 15 full-time staff as of the latest reporting period, reflecting a lean operational structure aimed at maintaining efficiency. The company continues to evaluate its distribution channels and may expand its e-commerce presence to enhance market access.
Looking ahead, Milestone Scientific anticipates the need for additional funding to support its operations and growth initiatives. The company has expressed concerns regarding its ability to continue as a going concern without raising sufficient capital. Management is focused on improving liquidity and operational results, but uncertainties remain regarding future revenue generation and market acceptance of its products. The company is also navigating regulatory changes and market conditions that could impact its business strategy and financial performance.
About MILESTONE SCIENTIFIC INC.
Milestone Scientific specializes in developing proprietary, computer-controlled drug delivery devices utilizing DPS Dynamic Pressure Sensing Technology. Its core products include pain-free dental anesthesia systems and epidural anesthesia devices, serving dental and medical markets worldwide. The company emphasizes safety, precision, and patient comfort, with regulatory approvals and patents supporting its innovative solutions. Its business model relies on licensing, distribution, and direct sales of advanced injection systems.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.